• 1
    Lloyd AR, Oppenheim JJ. Poly's lament: the neglected role of the polymorphonuclear neutrophil in the afferent limb of the immune response. Immunol Today 1992; 13:16972.
  • 2
    Cassatella MA. The production of cytokines by polymorphonuclear neutrophils. Immunol Today 1995; 16:216.
  • 3
    Bazzoni F, Cassatella MA, Rossi F, Ceska M, Dewald B, Baggiolini M. Phagocytosing neutrophils produce and release high amounts of the neutrophil-activating peptide 1/interleukin 8. J Exp Med 1991; 173:7714.
  • 4
    Wang P, Wu P, Anthes JC, Siegel MI, Egan RW, Billah MM. Interleukin-10 inhibits interleukin-8 production in human neutrophils. Blood 1994; 83:267883.
  • 5
    Altstaedt J, Kirchner H, Rink L. Cytokine production of neutrophils is limited to interleukin-8. Immunology 1996; 89:5638.
  • 6
    Cassatella MA, Meda L, Gasperini S, Calzetti F, Bonora S. Interleukin 10 (IL-10) upregulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation. J Exp Med 1994; 179:16959.
  • 7
    Bliss SK, Marshall AJ, Zhang Y, Denkers EY. Human polymorphonuclear leukocytes produce IL-12, TNF-alpha, and the chemokines macrophage-inflammatory protein-1 alpha and -1 beta in response to Toxoplasma gondii antigens. J Immunol 1999; 162:736975.
  • 8
    Kasama T, Strieter RM, Standiford TJ, Burdick MD, Kunkel SL. Expression and regulation of human neutrophil-derived macrophage inflammatory protein 1 alpha. J Exp Med 1993; 178:6372.
  • 9
    Kasama T, Strieter RM, Lukacs NW, Burdick MD, Kunkel SL. Regulation of neutrophil-derived chemokine expression by IL-10. J Immunol 1994; 152:355969.
  • 10
    Rudack C, Jorg S, Sachse F. Biologically active neutrophil chemokine pattern in tonsillitis. Clin Exp Immunol 2004; 135:5118.
  • 11
    Kita H, Ohnishi T, OkuboY, Weiler D, Abrams JS, Gleich GJ. Granulocyte/macrophage colony-stimulating factor and interleukin 3 release from human peripheral blood eosinophils and neutrophils. J Exp Med 1991; 174:7458.
  • 12
    Cassatella MA, Meda L, Gasperini S, D'Andrea A, Ma X, Trinchieri G. Interleukin-12 production by human polymorphonuclear leukocytes. Eur J Immunol 1995; 25:15.
  • 13
    Shirafuji N, Matsuda S, Ogura H et al. Granulocyte colony-stimulating factor stimulates human mature neutrophilic granulocytes to produce interferon-alpha. Blood 1990; 75:179.
  • 14
    Fava RA, Olsen NJ, Postlethwaite AE, Broadley KN, Davidson JM, Nanney LB, Lucas C, Townes AS. Transforming growth factor beta 1 (TGF-beta 1) induced neutrophil recruitment to synovial tissues: implications for TGF-beta-driven synovial inflammation and hyperplasia. J Exp Med 1991; 173:112132.
  • 15
    Grotendorst GR, Smale G, Pencev D. Production of transforming growth factor beta by human peripheral blood monocytes and neutrophils. J Cell Physiol 1989; 140:396402.
  • 16
    Szymkowiak CH, Csernok E, Reinhold D, Bank U, Gross WL, Kekow J. Neutrophils synthesize and activate TGF beta 2. Cytokine 2000; 12:397400.
  • 17
    Bronchud MH, Scarffe JH, Thatcher N, Crowther D, Souza LM, Alton NK, Testa NG, Dexter TM. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 1987; 56:80913.
  • 18
    Caspar CB, Seger RA, Burger J, Gmur J. Effective stimulation of donors for granulocyte transfusions with recombinant methionyl granulocyte colony-stimulating factor. Blood 1993; 81:286671.
  • 19
    Yoshida T, Nakamura S, Ohtake S et al. Effect of granulocyte colony-stimulating factor on neutropenia due to chemotherapy for non-Hodgkin's lymphoma. Cancer 1990; 66:19049.
  • 20
    Crawford J, Ozer H, Stoller R et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325:16470.
  • 21
    Smith WS, Sumnicht GE, Sharpe RW, Samuelson D, Millard FE. Granulocyte colony-stimulating factor versus placebo in addition to penicillin G in a randomized blinded study of gram-negative pneumonia sepsis: analysis of survival and multisystem organ failure. Blood 1995; 86:13019.
  • 22
    Kullberg BJ, Netea MG, Curfs JH, Keuter M, Meis JF, Van Der Meer JW. Recombinant murine granulocyte colony-stimulating factor protects against acute disseminated Candida albicans infection in nonneutropenic mice. J Infect Dis 1998; 177:17581.
  • 23
    Dunne JR, Dunkin BJ, Nelson S, White JC. Effects of granulocyte colony stimulating factor in a nonneutropenic rodent model of Escherichia coli peritonitis. J Surg Res 1996; 61:34854.
  • 24
    Tanaka H, Nishino M, Nakamori Y, Ogura H, Ishikawa K, Shimazu T, Sugimoto H. Granulocyte colony-stimulating factor (G-CSF) stiffens leukocytes but attenuates inflammatory response without lung injury in septic patients. J Trauma 2001; 51:11106.
  • 25
    Grigull L, Schrauder A, Schmitt-Thomssen A, Sykora K, Welte K. Efficacy and safety of G-CSF mobilized granulocyte transfusions in four neutropenic children with sepsis and invasive fungal infection. Infection 2002; 30:26771.
  • 26
    Cheng AC, Stephens DP, Anstey NM, Currie BJ. Adjunctive granulocyte colony-stimulating factor for treatment of septic shock due to melioidosis. Clin Infect Dis 2004; 38:327.
  • 27
    Dalhoff K, Hansen F, Dromann D, Schaaf B, Aries SP, Braun J. Inhibition of neutrophil apoptosis and modulation of the inflammatory response by granulocyte colony-stimulating factor in healthy and ethanol-treated human volunteers. J Infect Dis 1998; 178:8915.
  • 28
    Schober I, Braun R, Reiser H, Munk K, Leroux M, Kirchner H. la-positive T lymphocytes are the producer cells of interferon gamma. Exp Cell Res 1984; 152:34856.
  • 29
    Rink L, Nicklas W, Alvarez OL, Fagin U, Kirchner H. Microbial superantigens stimulate T cells by the superantigen bridge and independently by a cytokine pathway. J Interferon Cytokine Res 1997; 17:48999.
  • 30
    Laemmli UK. Cleavage of structural proteins during assembly of the head of bacteriophage-T4. Nature 1970; 227:6805.
  • 31
    Ju XS, Zenke M. Differentiation of human antigen-presenting dendritic cells from CD34+ hematopoietic stem cells in vitro. Methods Mol Biol 2003; 215:399407.
  • 32
    Hacker C, Kirsch RD, Ju XS et al. Transcriptional profiling identifies Id2 function in dendritic cell development. Nat Immunol 2003; 4:3806.
  • 33
    Ju XS, Hacker C, Madruga J, Kurz SM, Knespel S, Blendinger G, Rose-John S, Zenke M. Towards determining the differentiation program of antigen-presenting dendritic cells by transcriptional profiling. Eur J Cell Biol 2003; 82:7586.
  • 34
    Schreiber A, Otto B, Ju X, Zenke M, Goebel U, Luft FC, Kettritz R. Membrane proteinase 3 expression in patients with Wegener's granulomatosis and in human hematopoietic stem cell-derived neutrophils. J Am Soc Nephrol 2005; 16:221624.
  • 35
    Von Der Ohe M, Altstaedt J, Gross U, Rink L. Human neutrophils produce macrophage inhibitory protein-1beta but not type i interferons in response to viral stimulation. J Interferon Cytokine Res 2001; 21:2417.
  • 36
    Malyak M, Smith MF, Abel AA, Hance KR, Arend WP. The differential production of three forms of IL-1 receptor antagonist by human neutrophils and monocytes. J Immunol 1998; 161:200410.
  • 37
    Schröder AK, Von Der Ohe M, Fleischer D, Rink L, Uciechowski P. Differential synthesis of two interleukin-1 receptor antagonist variants and interleukin-8 by peripheral blood neutrophils. Cytokine 2005; 32:24653.
  • 38
    Bourke E, Cassetti A, Villa A, Fadlon E, Colotta F, Mantovani A. IL-1 beta scavenging by the type II IL-1 decoy receptor in human neutrophils. J Immunol 2003; 170:59996005.
  • 39
    Leonard EJ. NAP-1 (IL-8). Immunol Today 1990; 11:2234.
  • 40
    Zwahlen R, Walz A, Rot A. In vitro and in vivo activity and pathophysiology of human interleukin-8 and related peptides. Int Rev Exp Pathol 1993; 34 (Part B):2742.
  • 41
    Hayashi F, Means TK, Luster AD. Toll-like receptors stimulate human neutrophil function. Blood 2003; 102:26609.
  • 42
    Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993; 119:7718.
  • 43
    Glauser MP, Zanetti G, Baumgartner JD, Cohen J. Septic shock: pathogenesis. Lancet 1991; 338:7326.
  • 44
    Tsao TCY, Hong J, Li LF, Hsieh MJ, Liao SK, Chang KSS. Imbalances between tumor necrosis factor-alpha and its soluble receptor forms, and interleukin-1 beta and interleukin-1 receptor antagonist in BAL fluid of cavitary pulmonary tuberculosis. Chest 2000; 117:1039.
  • 45
    Krolling UK, Hansen F, Braun J, Rink L, Katus HA, Dalhoff K. Leucocyte response and anti-inflammatory cytokines in community acquired pneumonia. Thorax 2001; 56:1215.
  • 46
    Rupp J, Kothe H, Mueller A, Maass M, Dalhoff K. Imbalanced secretion of IL-1beta and IL-1RA in Chlamydia pneumoniae-infected mononuclear cells from COPD patients. Eur Respir J 2003; 22:2749.
  • 47
    Kobayashi SD, Voyich JM, Braughton KR, Whitney AR, Nauseef WM, Malech HL, Deleo FR. Gene expression profiling provides insight into the pathophysiology of chronic granulomatous disease. J Immunol 2004; 172:63643.
  • 48
    Saccani A, Saccani S, Orlando S, Sironi M, Bernasconi S, Ghezzi P, Mantovani A, Sica A. Redox regulation of chemokine receptor expression. Proc Natl Acad Sci USA 2000; 97:27616.
  • 49
    Michalec L, Choudhury BK, Postlethwait E, Wild JS, Alam R, Lett-Brown M, Sur S. CCL7 and CXCL10 orchestrate oxidative stress-induced neutrophilic lung inflammation. J Immunol 2002; 168:84652.
  • 50
    Malech HL, Nauseef WM. Primary inherited defects in neutrophil function: etiology and treatment. Semin Hematol 1997; 34:27990.
  • 51
    Lekstrom-Himes JA, Gallin JI. Immunodeficiency diseases caused by defects in phagocytes. N Engl J Med 2000; 343:170314.
  • 52
    Halamish A, Klar A, Shoseyov D, Blinder G, Hurvitz H. Corticosteroid therapy reversed progressive chronic granulomatous lung disease following deterioration on interferon-gamma treatment. Pediatr Pulmonol 2001; 32:25760.
  • 53
    Chin TW, Stiehm ER, Falloon J, Gallin JI. Corticosteroids in treatment of obstructive lesions of chronic granulomatous disease. J Pediatr 1987; 111:34952.
  • 54
    Conti P, Panara MR, Fridas S, Barbacane RC, Grilli A, Placido FC, Reale M, Fiore S. Inhibition of granuloma formation induced by potassium permanganate in the mouse by a specific human recombinant receptor antagonist for interleukin-1 (hrIL-1ra). Cell Immunol 1993; 147:44657.
  • 55
    Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998; 16:2755.
  • 56
    Rink L, Kirchner H. Recent progress in the tumor necrosis factor-alpha field. Int Arch Allergy Immunol 1996; 111:199209.
  • 57
    Wiedermann FJ, Mayr AJ, Hobisch-Hagen P, Fuchs D, Schobersberger W. Association of endogenous G-CSF with anti-inflammatory mediators in patients with acute respiratory distress syndrome. J Interferon Cytokine Res 2003; 23:72936.
  • 58
    Stephens DP, Fisher DA, Currie BJ. An audit of the use of granulocyte colony-stimulating factor in septic shock. Intern Med J 2002; 32:1438.
  • 59
    Schneider C, Von Aulock S, Zedler S, Schinkel C, Hartung T, Faist E. Perioperative recombinant human granulocyte colony-stimulating factor (Filgrastim) treatment prevents immunoinflammatory dysfunction associated with major surgery. Ann Surg 2004; 239:7581.
  • 60
    Xing LY, Remick DG. Neutrophils as firemen, production of anti-inflammatory mediators by neutrophils in a mixed cell environment. Cell Immunol 2004; 231:12632.
  • 61
    Klein JB, Rane MJ, Scherzer JA, Coxon PY, Kettritz R, Mathiesen JM, Buridi A, McLeish KR. Granulocyte-macrophage colony-stimulating factor delays neutrophil constitutive apoptosis through phosphoinositide 3-kinase and extracellular signal-regulated kinase pathways. J Immunol 2000; 164:428691.